Filter
2056
Filtered Results: 2056
Text search:
Dowse,
R.
Featured
Recommendations
253
New Publications
426
Language
Document type
No document type
1043
Guidelines
412
Studies & Reports
329
Manuals
116
Training Material
49
Strategic & Response Plan
46
Fact sheets
40
Situation Updates
10
Infographics
6
Brochures
3
Resource Platforms
2
Countries / Regions
India
125
Global
98
South Africa
51
Kenya
38
Latin America and the Carribbean
38
Brazil
38
Nepal
32
Senegal
30
Africa
29
Western and Central Europe
26
Tanzania
25
Congo, Democratic Republic of
23
Philippines
22
Ethiopia
22
Zambia
21
Uganda
20
Malawi
19
Nigeria
18
Bangladesh
17
Sierra Leone
16
Zimbabwe
16
Rwanda
15
Mozambique
15
Indonesia
14
Ghana
13
Burkina Faso
12
Germany
12
Liberia
12
West and Central Africa
11
Eastern Europe
11
Ukraine
10
Asia
10
South–East Asia Region
10
Haiti
9
Benin
8
Cameroon
8
Cambodia
8
Myanmar / Burma
8
Madagascar
8
Syria
7
Namibia
7
Tajikistan
6
Thailand
6
Afghanistan
6
Argentina
6
Russia
6
Pakistan
6
North America
5
East and Southern Africa
5
Angola
5
South Sudan
5
Lesotho
4
USA
4
Middle East and North Africa
4
France
4
Vietnam
4
Sudan
4
Botswana
4
Eswatini/ Swaziland
4
Albania
3
Guinea
3
Guinea-Bissau
3
Venezuela
3
Eastern Europe and Central Asia
3
Lebanon
3
Sri Lanka
3
Chad
3
Iraq
3
Somalia
3
Kazakhstan
2
Chile
2
Iran
2
Peru
2
Morocco
2
Qatar
2
Jordan
2
Saudi Arabia
2
Paraguay
2
United Kingdom
2
Portugal
2
Côte d’Ivoire / Ivory Coast
2
Georgia
2
Central African Republic
2
Mali
2
North Macedonia
1
Colombia
1
Timor Leste/ East Timor
1
Mexico
1
El Salvador
1
Turkey
1
Gambia
1
Togo
1
Canada
1
Laos
1
Estonia
1
Kyrgyzstan
1
Congo-Brazzaville
1
Niger
1
Burundi
1
Malaysia
1
Jamaica
1
Denmark
1
Tunisia
1
Spain
1
Latvia
1
Southern Africa
1
Papua New Guinea
1
Djibouti
1
Egypt
1
Yemen
1
Greece
1
Palestine
1
Libya
1
Bhutan
1
Ecuador
1
Solomon Islands
1
Authors & Publishers
Publication Years
Category
Countries
652
Clinical Guidelines
358
Women & Child Health
149
Public Health
125
Key Resources
58
Capacity Building
31
Pharmacy & Technologies
13
Toolboxes
COVID-19
187
TB
177
HIV
164
Mental Health
136
NTDs
113
AMR
79
NCDs
77
Pharmacy
63
Caregiver
60
Rapid Response
52
Ebola & Marburg
36
Planetary Health
33
Conflict
26
Refugee
25
Cholera
24
Specific Hazards
21
Malaria
19
Polio
18
Global Health Education
14
Health Financing Toolbox
9
Disability
8
Zika
7
Natural Hazards
4
Social Ethics
4
The Pharmacovigilance team in WHO aims to assure the safety of medicines and vaccines by ensuring reliable and timely exchange of information on safety issues, promoting pharmacovigilance activities throughout the Organization and encouraging participation in the WHO Programme for International Drug...
The Priority medicines for mothers and children 2011 list was updated following the 18th Expert Committee Meeting
on Selection and Use of Medicines, the release of new treatment guidelines and feedback from partners following
the 2011 version. In alignment with the UN Global strategy f...
With the goal of ending viral hepatitis as a public health threat by 2030, the Regional Action Plan will provide an actionable framework for implementing evidence-based interventions at scale. It will be informed through strategic monitoring of the response, that must be equitable and sustainable an...
orientations provisoires, première publication : 8 janvier 2021, mise à jour : 15 juin 2021, mise à jour : 19 novembre 2021, mise à jour : 21 janvier 2022
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th...
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el
mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este
antirretrovírico en las poblaciones tratadas con esquemas que lo conti...
During the 17 years since Surgical approaches to the urogenital manifestations of lymphatic filariasis was first published, there has been heightened awareness of the physical, economic and emotional burden of the genitourinary manifestations of filariasis. With the impetus to provide better guidanc...
Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial infarction, stroke and peripheral arterial disease continue to be major causes of premature death, disability and healthcare expenditure globally. Preventing the accumulation of cholesterol-containing atherogenic lipopr...
Troisième édition 2016
A WHO-ITU Standard.
Nearly 50% of people aged 12-35 years – or 1.1 billion young people – are at risk of hearing loss due to prolonged and excessive exposure to loud sounds, including music they listen to through personal audio devices. Ahead of World Hearing Day (3 March), the World Health Org...
Understanding Cultural Diversity in Mental Health
Downloaded from https://aidsinfo.nih.gov/guidelines on 11/27/2019
Visit the AIDSinfo website to access the most up-to-date guideline.
Register for e-mail notification of guideline updates at https://aidsinfo.nih.gov/e-news.
Malawi Integrated Guidelines and Standard Operating Procedures for Providing HIV Services. 3rd edition 2016
The purpose of this guidance is to assist WHO Member States, and other stakeholders, in the establishment and development of programmes of integrated surveillance of antimicrobial resistance in foodborne bacteria (i.e., bacteria commonly transmitted by food). In this guidance, “integrated surveill...
The World Health Organization (WHO) has recommended a universal antiretroviral therapy (ART) for all HIVinfected children before the age of two since 2010, but this implies an early identification of these infants. We described the Prevention of Mother-to-Child HIV Transmission (PMTCT) cascade, the ...
These guidelines for the prevention and management of cardiovascular diseases are a critical ingredient for streamlining care across the entire health services provision continuum. They are a strategic component in achieving universal health coverage, securing affordable heal...
Overview
16 Dec 2021. This interim guidance pertains to heterologous primary and heterologous boosting schedules of Covid-19 vaccines. It focuses on heterologous schedules combining multiple vaccine platforms (e.g. a vectored vaccine followed by an mRNA vaccine).
